Interviews with patients across 15 US states reveal that GLP-1 drugs serve as powerful facilitators of weight management, but are not miracle cures, with long-term success depending on support, affordability, side-effect management, and reduced stigma, according to a study published in JAMA Network Open on June 8.
The qualitative study involved interviews with 30 adults from diverse backgrounds who were either currently using or had previously used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management or related health conditions. Most participants had type 2 diabetes. Researchers conducted the interviews via video conferencing between July and September of the previous year.
Participants described a significant decrease in what they called "food noise," referring to persistent thoughts about food and constant cravings. Many said this allowed them greater control over eating behaviors and better food choices. However, most emphasized that the medication was not a miracle cure and reported supporting their weight loss through healthy lifestyle changes such as improved diet planning and increased physical activity.
Adverse effects ranged from mild nausea to severe gastrointestinal issues like vomiting and diarrhea. Some participants found mild discomfort helpful as it signaled fullness. Despite these challenges, many were willing to tolerate unpleasant symptoms due to perceived benefits in weight loss. Barriers such as medication shortages, cost concerns, insurance coverage gaps, and stigma associated with using weight-loss medications also shaped patient experiences.
Participants highlighted differences in public perception: those using GLP-1 RAs for diabetes felt less judged than those using them for obesity treatment. Experiences with healthcare providers varied; while some praised clear guidance from clinicians, others noted insufficient counseling about side effects or long-term management needs. Many expressed a need for more practical information regarding adverse effects and follow-up care.
The study concluded that GLP-1 RAs can help patients regain control over eating behaviors but should be viewed as part of an overall approach including diet and exercise rather than standalone solutions. The authors cautioned that because this was a small qualitative study involving only 30 participants—and possibly subject to selection bias—the findings should not be generalized to all users.
